Liminatus Pharma, Inc. LIMN
2.80 USD +0.01 (+0.38%)
Nov 4, 2026, 1:46 PM EST
2.66 Day range 2.95
2.40 52-week range 141.50
- YTD
- -90.82%
- 1 year
- -95.59%
Financial health
Altman Z-Score
-28.24 Distress zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
2 / 9 Weak
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
D+1 / 5 overall
- DCF 1
- Return on Equity 1
- Return on Assets 1
- Debt / Equity 1
- P/E 1
- P/B 1
Valuation
P/E -1.4×
FY 2021 5y median -12.5× FY 2025
P/S 0.0×
FY 2021 5y median 0.0× FY 2025
P/B -1.5×
FY 2021 5y median -1.5× FY 2025
P/FCF -1.5×
FY 2021 5y median -12.0× FY 2025
EV/EBITDA -1.6×
FY 2021 5y median -14.7× FY 2025
EV/Sales 0.0×
FY 2021 5y median 0.0× FY 2025
FCF Yield -68.9%
FY 2021 5y median -8.3% FY 2025
Profitability
Gross Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Operating Margin 0.0%
FY 2021 5y median 0.0% FY 2025
Net Margin 0.0%
FY 2021 5y median 0.0% FY 2025
ROE 104.0%
FY 2021 5y median 11.5% FY 2025
ROIC 35.6%
FY 2021 5y median -0.9% FY 2025
ROA -1990.4%
FY 2021 5y median -27.2% FY 2025
Growth (YoY)
Revenue 0.0%
FY 2021 FY 2025
Operating Income -2.1%
FY 2021 FY 2025
EPS (diluted) -7.5%
FY 2021 FY 2025
Free Cash Flow -221.2%
FY 2021 FY 2025
Financial Health
Current Ratio 0.0×
FY 2021 5y median 0.1× FY 2025
Quick Ratio 0.0×
FY 2021 5y median 0.1× FY 2025
Debt / Equity -0.1×
FY 2021 5y median -0.1× FY 2025
Net Debt / EBITDA -0.1×
FY 2021 5y median -1.6× FY 2025
Interest Coverage -13.7×
FY 2021 5y median -13.7× FY 2025
Dividends
Dividend Yield 0.0%
FY 2021 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2021 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31